Jump to ContentJump to Main Navigation
Show Summary Details
More options …


Perspektiven der Wirtschaftspolitik

Editor-in-Chief: Haucap, Justus

Ed. by Arnold, Lutz / Corneo, Giacomo / Grimm, Veronika / Horn, Karen / Schneider, Friedrich / Wagner, Franz / Winter, Joachim

CiteScore 2018: 0.37

SCImago Journal Rank (SJR) 2018: 0.225
Source Normalized Impact per Paper (SNIP) 2018: 0.798

See all formats and pricing
More options …
Volume 16, Issue 2


Vergleichbarkeit internationaler Arzneimittelpreise

Internationale Preisreferenzierung in Deutschland durch das AMNOG

Dr. Jörg Mahlich / Dr. Jörn Sindern / Moritz Suppliet
  • Düsseldorf Institute for Competition Economics (DICE), Heinrich Heine-Universität Düsseldorf, Universitätsstr. 1, 40225 Düsseldorf
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2015-06-10 | DOI: https://doi.org/10.1515/pwp-2015-0012


This paper shows that a recent change in the German pharmaceutical reimbursement legislation [AMNOG] allows the introduction of a reference pricing system [IRP] which improves social welfare by enhancing access to innovative drugs. In particular, the adjustment of foreign pharmaceutical prices by GDP per capita in purchasing power parities would incentivize pharmaceutical firms to differentiate drug prices according to national income. Results for the active ingredient Abirateronacetat [Zytiga®] indicate price differentials of up to 43 percentage points across Europe and an increase in global welfare by improving access to medicine and by strengthening economic incentives to invest in research and development.


  • Breyer, F., Zweifel, P. und M. Kifmann (2013): Preisregulierung der Arzneimittel. in: Breyer, F., Zweifel, P., und M. Kifmann (Hrsg.): Gesundheitsökonomik, Vol. 6, Berlin, Springer, S. 498–508.Google Scholar

  • Burg, F. (2011): Zur Berechnung von Kaufkraftparitäten. Wirtschaft und Statistik, Nr. 8, S. 793–801.Google Scholar

  • Carone, G., Schwierz, C. und A. Xavier (2012): Cost-containment Policies in Public Pharmaceutical Spending in the EU. Europäische Kommission – Directorate-General for Economic and Financial Affairs, Economic Papers 461.Google Scholar

  • Cassel, D. und V. Ulrich (2012): Herstellerabgabepreise auf europäischen Arzneimittelmärkten als Erstattungsrahmen in der GKV‐Arzneimittelversorgung: Zur Problematik des Konzepts internationaler Vergleichspreise. Gutachten für den VFA, Berlin.Google Scholar

  • Culyer, A.J. (1982): The NHS and the Market: Images and Realities. In: Maynard, A., und G. McLachlan (Hrsg.), The Public-Private Mix for Health: The Relevance and Effects of Change, Nuffield Provincial Hospitals Trust, London, S. 23–55.Google Scholar

  • Danzon, P. M. (1997): Price Discrimination for Pharmaceuticals: Welfare Effects in the US and the EU. International Journal of the Economics of Business, 4(3), S. 301–322.Google Scholar

  • Danzon, P. und A. Towse (2003): Differential pricing for pharmaceuticals: reconciling access, R&D and patents. International Journal of Health Care Finance and Economics, 3(3), S. 183–205.CrossrefGoogle Scholar

  • Danzon, P., Towse, A. und J. Mestre-Ferrandiz (2013): Value-based differential pricing: Efficient prices for drugs in a global context. Health Economics, 22(12), S. 1405–1514.Google Scholar

  • Deutscher Bundestag (2012): Änderungsantrag 2 – Änderung des Fünften Buches Sozialgesetzbuch. BT-Drucks 17/9341, Berlin.Google Scholar

  • Égert, B. (2007): Real convergence, price level convergence and inflation differentials in Europe. CESifo Working Paper No. 2127.Google Scholar

  • Europäische Kommission (2009a): Das BIP und mehr. Die Messung des Fortschritts in einer Welt im Wandel. Mitteilung der Europäischen Kommission an den Rat und das Europäische Parlament. KOM (2009), 433, Brüssel.Google Scholar

  • Europäische Kommission (2009b): Pharmaceutical Sector Inquiry – Final Report. Europäische Kommission – DG Competition. Abgerufen am 18.08.2013, von: http://ec.europa.eu/competition/sectors/pharmaceuticals/inquiry/.

  • Eurostat (2012): Eurostat-OECD Methodological Manual on Purchasing Power Parities. EUROSTAT-OECD, Paris.Google Scholar

  • Gerdtham, U. und B. Jonsson (1991): Conversion factor instability in international comparisons of health care expenditure. Journal of Health Economics, 10(2), S. 227–234.CrossrefGoogle Scholar

  • Hall, R. und C. Jones (2007): The Value of Life and the Rise in Health Spending. Quarterly Journal of Economics 122, S. 39–72.Google Scholar

  • Herr, A. und M. Suppliet (2012): Pharmaceutical prices under regulation: Tiered co-payments and reference pricing in Germany. DICE Discussion Paper 48.Google Scholar

  • Hitiris, T. und J. Posnett (1992): The determinants and effects of health expenditure in developed countries. Journal of Health Economics, 11(2), S. 173–181.CrossrefGoogle Scholar

  • Jaumotte, F. und H. Morsy (2012): Determinants of inflation in the Euro Area: the role of labor and product market institutions. IMF Working Paper 12/37.Google Scholar

  • Krugman, P. (1987): Pricing to Market When the Exchange Rate Changes. In: Arndt, S.W. und J.D. Richardson (Hrsg.): Real-financial linkages among open economies. MIT Press, Cambridge S. 49–70.Google Scholar

  • Kyle, M. (2007): Pharmaceutical price controls and entry strategies. The Review of Economics and Statistics, 89(1), S. 88–99.Google Scholar

  • Kyle, M. (2011): Strategic responses to parallel trade. The BE Journal of Economic Analysis & Policy, 11(2), S. 1–32.Google Scholar

  • Malueg, D. und M. Schwartz (1994): Parallel imports, demand dispersion, and international price discrimination. Journal of International Economics, 37(3–4), S. 167–195.CrossrefGoogle Scholar

  • Moscone, F. und E. Tosetti (2010): Health expenditure and income in the United States. Health Economics, 19(12), S. 1385–1403.Google Scholar

  • Neubauer, G., Morasch, K. und A. Gmeiner (2013): Möglichkeiten und Vorteile einer Preisdifferenzierung bei innovativen Arzneimitteln. Studie für den Verband Forschender Arzneimittelhersteller e.V., Berlin.Google Scholar

  • OECD (2003): A Disease-based Comparison of Health Systems: What is Best and at What Costs? OECD, Paris.Google Scholar

  • Parkin, D., McGuire, A. und B. Yule (1987): Aggregate health care expenditures and national income: is health care a luxury good? Journal of Health Economics, 6(2), S. 109–127.CrossrefGoogle Scholar

  • Przybyla, M. und M. Roma (2005): Does Product Market Competition Reduce Inflation? Evidence from EU Countries and Sectors. European Central Bank, Working Paper Series 453.Google Scholar

  • Richardson, M. (2002): An elementary proposition concerning parallel imports. Journal of International Economics, 56(1), S. 233–245.Google Scholar

  • Rogoff, K. (1996): The purchasing power parity puzzle. Journal of Economic Literature, 34(2), S. 647–668.Google Scholar

  • Scherer, F. und J. Watal (2002): Post‐TRIPS Options for Access to Patented Medicines in Developing Nations. Journal of International Economic Law, 5(4), S. 913–939.CrossrefGoogle Scholar

  • Schreyögg, J., Tiemann, O., Stargardt, T. und R. Busse (2008): Cross-country comparisons of costs: the use of episode-specific transitive purchasing power parities with standardised cost categories. Health Economics, 17(S1), S. 95–103.CrossrefGoogle Scholar

  • Taylor, A.M. und M.P. Taylor (2004): The purchasing power parity debate. Journal of Economic Perspectives, 18(4), S. 135–58.CrossrefGoogle Scholar

About the article

Published Online: 2015-06-10

Published in Print: 2015-06-01

Citation Information: Perspektiven der Wirtschaftspolitik, Volume 16, Issue 2, Pages 164–172, ISSN (Online) 1468-2516, ISSN (Print) 1465-6493, DOI: https://doi.org/10.1515/pwp-2015-0012.

Export Citation

© 2015 Walter de Gruyter GmbH, Berlin/München/Boston.Get Permission

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

Jörg Mahlich, Jörn Sindern, and Moritz Suppliet
Expert Review of Pharmacoeconomics & Outcomes Research, 2018, Page 1

Comments (0)

Please log in or register to comment.
Log in